Related Experiment Video

Updated: May 6, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

SMARCA4/BRG1-deficient NSCLC: a case report and literature review

He Zhang1, Xiong-Wen Tu1, Yu-Qing Wei1

  • 1Department of Respiratory and Critical Care Medicine, Yijishan Hospital, The first Affiliated Hospital of Wannan Medical College, Wuhu, China.

JPMA. the Journal of the Pakistan Medical Association
|November 17, 2025
PubMed

Insights

This case study highlights a promising comprehensive treatment for non-small cell lung cancer (NSCLC) patients with SMARCA4 deficiency. The approach maintained patient quality of life and prevented disease progression, offering hope for this challenging subgroup.

Area of Science:

  • Oncology
  • Medical Case Study
  • Cancer Research

Background:

  • Non-small cell lung cancer (NSCLC) patients with SMARCA4 deficiency often present with advanced disease and poor prognosis.
  • Current treatments, including immune checkpoint inhibitors (ICIs) and chemotherapy, show suboptimal efficacy in this specific patient group.

Purpose of the Study:

  • To report a case of successful comprehensive treatment for a patient with SMARCA4-deficient NSCLC.
  • To illustrate a potential therapeutic strategy for improving outcomes in this challenging patient population.

Main Methods:

  • A single patient with SMARCA4-deficient NSCLC was treated using a comprehensive therapeutic approach.
  • Treatment details and patient outcomes were monitored post-intervention.

Main Results:

  • The patient demonstrated a satisfactory general condition and improved quality of life (QOL).
  • No disease progression was observed following the comprehensive treatment regimen.
  • The treatment was well-tolerated, suggesting a favorable safety profile.

Conclusions:

  • Comprehensive treatment strategies may offer a viable option for managing SMARCA4-deficient NSCLC.
  • Further research is warranted to explore the efficacy and applicability of such treatments in a broader patient cohort.
  • This case underscores the need for personalized treatment approaches in NSCLC based on molecular characteristics like SMARCA4 deficiency.
Keywords:
NSCLC, SMARCA4-deficient, Treatment, Prognosis.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

305

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K